Holen Sie sich die Stockscreener-App
20.00
4.31%
-0.90
Handel nachbörslich:
20.00
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
Why ArriVent BioPharma Inc. stock is favored by pension fundsJuly 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with multi timeframe charts2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Is ArriVent BioPharma The Next Big Player In Targeted Cancer Therapies? - RTTNews
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
What’s the recovery path for long term holders of ArriVent BioPharma Inc.July 2025 Institutional & Weekly Breakout Watchlists - newser.com
Is ArriVent BioPharma Inc. stock attractive after correctionWeekly Market Report & Low Volatility Stock Recommendations - newser.com
Should you hold or exit ArriVent BioPharma Inc. nowJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Can volume confirm reversal in ArriVent BioPharma Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
ArriVent BioPharma (NASDAQ:AVBP) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will ArriVent BioPharma Inc. stock see PE expansion2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Is it too late to sell ArriVent BioPharma Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - newser.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Trend Recap & Smart Money Movement Tracker - newser.com
How moving averages guide ArriVent BioPharma Inc. tradingTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN
Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com
Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com
ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria
ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz
ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks
Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener
ArriVent BioPharma Names Brent S. Rice as CCO - MarketScreener
ArriVent BioPharma Announces Appointment of Brent S. Rice as Chief Commercial Officer - Quiver Quantitative
ArriVent Appoints Brent S. Rice as Chief Commercial Officer - The Manila Times
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):